AFA
BIO icon

Abacus FCF Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Abacus FCF Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,408
Closed -$674K – 138
2023
Q1 		$674K Buy
1,408
+180
+15% +$84.3K 0.36% 115
2022
Q4 		$516K Sell
1,228
-27
-2% -$10.9K 0.34% 124
2022
Q3 		$523K Buy
+1,255
New +$626K 0.36% 128

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Abacus FCF Advisors's BIO Position: Q2 2023 in Review

Abacus FCF Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 1,408 shares — an estimated $674K sold.

Abacus FCF Advisors first reported a position in BIO in Q3 2022 and held it in 3 quarters. The position peaked at $674K in Q1 2023. 468 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Abacus FCF Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Abacus FCF Advisors sold 1,408 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $674K.
  • Abacus FCF Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 3 quarters.
  • Abacus FCF Advisors's Bio-Rad Laboratories Class A position peaked at $674K in Q1 2023.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Abacus FCF Advisors's 13F filing for Q2 2023, filed 19 Jul 2023.